Biopharmaceutical characterisation of ciprofloxacin-metallic ion interactions: Comparative study into the effect of aluminium, calcium, zinc and iron on drug solubility and dissolution

Open access

Abstract

Ciprofloxacin bioavailability may be reduced when ciprofloxacin is co-administered with metallic ion containing preparations. In our previous study, physicochemical interaction between ciprofloxacin and ferrous sulphate was successfully simulated in vitro. In the present work, comparative in vitro ciprofloxacin solubility and dissolution studies were performed in the reactive media containing aluminium hydroxide, calcium carbonate or zinc sulphate. Solid phases collected from the dissolution vessel with aluminium hydroxide, calcium carbonate and zinc sulphate were investigated for their properties. The results obtained indicate that different types of adducts may form and retard ciprofloxacin solubility and dissolution. In the case of aluminium, no phase changes were observed. The solid phase generated in the presence of calcium carbonate was identified as hydrated ciprofloxacin base. Similarly to iron, a new complex consistent with Zn(SO4)2(Cl)2(ciprofloxacin)2 × nH2O stoichiometry was generated in the presence of relatively high concentrations of ciprofloxacin hydrochloride and zinc sulphate, indicating that small volume dissolution experiments can be useful for biorelevant dissolution tests.

1. J. R. Brouwers, H. J. Van der Kam, J. Sijtsma and J. H. Proost, Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate, Pharm. Weekbl. Sci. 12 (1990) 182-183; DOI: 10.1007/BF01980042.

2. R. W. Frost, J. T. Lettieri, A. Noe, E. C. Shamblen and K. Lasseter, Effect of aluminium hydroxide and calcium carbonate antacids on ciprofloxacin bioavailability, Antimicrob. Agents Chemother. 36 (1992) 830-832; DOI: 10.1128/AAC.36.4.830.

3. M. Kara, B. B. Hasinoff, W. D. McKay and R. C. N. Campbell, Clinical and chemical interactions between iron preparations and ciprofloxacin, Brit. J. Clin. Pharmacol. 31 (1991) 257-261; DOI: 10.1111/j.1365-2125.1991.tb05526.x.

4. P. Lehto, T. K. Kivisto and J. P. Neuvonen, The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin, Brit. J. Clin. Pharmacol. 37 (1994) 82-85; DOI: 10.1111/ j.1365-2125.1994.tb04245.x.

5. R. E. Polk, D. P. Healy, J. Sahai, L. Drwal and E. Racht, Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers, Antimicrob. Agents Chemother. 33 (1989) 1841-1844; DOI: 10.1128/AAC.33.11.1841.

6. D. E. Nix, W. A. Watson, M. E. Lener, R. W. Frost, G. Krol, H. Goldstein, J. Lettieri and J. J. Schentag, Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin, Clin. Pharmacol. Ther. 46 (1989) 700-705; DOI: 10.1038/clpt.1989.207.

7. E. Pazzucconi, S. Barbi, D. Baldassarre, N. Colombo, F. Dorigotti and C. R. Sirtori, Iron-ovotransferrin preparation does not interfere with ciprofloxacin absorption, Clin. Pharmacol. Ther. 59 (1996) 418-422; DOI: 10.1016/S0009-9236(96)90110-1.

8. A. L. Neuhofel, J. H.Wilton, J. M. Victory, L. G. Hejmanowsk and G.W. Amsden, Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction, J. Clin. Pharmacol. 42 (2002) 461-466; DOI: 10.1177/00912700222011391.

9. J. Sahai, D. P. Healy, J. Stotka and R. E. Polk, The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin, Brit. J. Clin. Pharmacol. 35 (1993) 302-304.

10. F. Kozjek, E. Palka, I. Krizman and P. Vodopivec, Pharmacokinetics of ciprofloxacin metal complexes, Acta Pharm. 46 (1996) 109-114.

11. S. Rodriguez Cruz, I. Gonzalez Alonso, A. Sanchez-Navarro and L. Sayalero Marinero, In vitro study of the interaction between quinolones and polyvalent cations, Pharm. Acta Helv. 73 (1999) 237-245; DOI: 2048/10.1016/S0031-6865(98)00029-6.

12. S. Žakelj, K. Berginc, D. Uršic, M. Veber and A. Kristl, Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier, J. Pharm. Biomed. Anal. 53 (2010) 655-659; DOI: 10.1016/j.jpba.2010.05.021.

13. K. Papai, M. Budai, K. Ludanyi, I. Antal and I. Klebovich, In vitro food-drug interaction study: Which milk component has a decreasing effect on the bioavailability of ciprofloxacin? J. Pharm. Biomed. Anal. 52 (2010) 37-42; DOI: 10.1016/j.jpba.2009.12.003.

14. J. Parojčić, A. Stojkovi}, L. Tajber, S. Grbi}, K. Paluch, Z. Duri} and O. I. Corrigan, Biopharmaceutical characterization of ciprofloxacin HCl-ferrous sulfate interaction, J. Pharm. Sci. 100 (2011) 5174-5184; DOI: 10.1002/jps.22707.

15. I. Turel, The interactions of metal ions with quinolone antibacterial agents, Coord. Chem. Rev. 232 (2002) 22-47; DOI: 10.1016/S0010-8545(02)00027-9.

16. A. K. Chattah, Y. G. Linck, G. A.Monti, P. R. Levstein, S. A. Breda, R. H. Manzo and M. E. Olivera, NMR and IR characterization of the aluminium complexes of norfloxacin and ciprofloxacin fluoroquinolones, Magn. Reson. Chem. 45 (2007) 850-859; DOI: 10.1002/mrc.2058.

17. L. Tajber, D. O. Corrigan, O. I. Corrigan and A. M. Healy, Spray drying of budesonide, formoterol fumarate and their composites - I. Physicochemical characterization, Int. J. Pharm. 367 (2009) 79-85; DOI: 10.1016/j.ijpharm.2008.09.030.

18. T. Bergan, S. B. Thorsteinsson, I. M. Kolstad and S. Johnsen, Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses, Eur. J. Clin. Microbiol. 5 (1986) 187-192; DOI: 10.1007/BF02013984.

19. K. Borner, G. Hoffken, H. Lode, P. Koeppe, C. Prinzing, P. Glatzel, R. Wiley, P. Olschewski, B. Sievers and D. Reinitz, Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration, Eur. J. Clin. Microbiol. 5 (1986) 179-186; DOI: 10.1007/BF02013983.

20. G. L. Drusano, H. C. Standiford, K. Plaisance, A. Forrest, J. Leslie and J. Caldwell, Absolute oral bioavailability of ciprofloxacin, Antimicrob. Agents Chemother. 30 (1986) 444-446; DOI: 10.1128/ AAC.30.3.444.

21. G. Hoffken, H. Lode, C. Prinzing, K. Borner and P. Koeppem, Pharmacokinetics of ciprofloxacin after oral and parenteral administration, Antimicrob. Agents Chemother. 27 (1985) 375-379; DOI: 10.1128/AAC.27.3.375.

22. J. T. Lettieri, M. C. Rogge, L. Kaiser, R. M. Echols and A. H. Heller, Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses, Antimicrob. Agents Chemother. 36 (1992) 993-996; DOI: 10.1128/AAC.36.5.993.

23. K. I. Plaisance, G. L. Drusano, A. Forrest, C. I. Bustamante and H. C. Standiford, Effect of dose size on bioavailability of ciprofloxacin, Antimicrob. Agents Chemother. 131 (1987) 956-958; DOI: 10.1128/AAC.31.6.956.

24. H. Lode, Drug interactions with quinolones, Clin. Infect. Dis. 10 (1988) S132-S136; DOI: 10.1093/ clinids/10.Supplement_1.S132.

25. S. Harder, U. Fuhr, D. Beermann and A. H. Staib, Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with hf-capsule, Brit. J. Clin. Pharmacol. 30 (1990) 35-39; DOI: 10.1111/j.1365-2125.1990.tb03740.x.

26. H. Kathyayini, I. Willems, A. Fonseca, J. B. Nagy and N. Nagaraju, Catalytic materials based on aluminium hydroxide, for the large scale production of bundles of multi-walled (MWNT) carbon nanotubes, Catal. Commun. 7 (2006) 140-147; DOI: 10.1016/j.catcom.2005.05.010.

27. S. Qing Su, J. Yang, H.W. Ma, F. Jiang, Y. Q. Liu and G. Li, Preparation of ultrafine aluminum hydroxide from coal fly ash by alkali dissolution process, Integr. Ferroelectr. 128 (2011) 155-162; DOI: 10.1080/10584587.2011.576626.

28. S. A. Breda, A. F. Jimenez-Kairuz, R. H. Manzo and M. E. Olivera, Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives, Int. J. Pharm. 371 (2009) 106-113; DOI: 10.1016/j.ijpharm.2008.12.026.

29. L. Mafra, S. M. Santos, R. Siegel, I. Alves, F. A. Almeida Paz, D. Dudenko and H. W. Spiess, Packing interactions in hydrated and anhydrous forms of the antibiotic ciprofloxacin: a solid-state NMR, X-ray diffraction, and computer simulation study, J. Am. Chem. Soc. 134 (2012) 71-74; DOI: 10.1021/ja208647n.

30. V. L. Dorofeev, The betaine like structure and infrared spectra of drugs of the fluoroquinolone group, Pharm. Chem. J. 38 (2004) 698-702; DOI: 10.1007/s11094-005-0064-5.

31. M. Zupančić, I. Turel, P. Bukovec, A. J. P. White and D. J. Williams, Synthesis and characterization of two novel zinc(II) complexes with ciprofloxacin crystal structure of [C17H19N3O3F]2 ZnCl4 2H2O, Croat. Chem. Acta. 74 (2001) 61-74.

32. R. Takano, N. Takata, R. Saito, K. Furumoto, S. Higo, Y. Hayashi, M. Machida, Y. Aso and S. Yamashita, Quantitative analysis of the effect of supersaturation on in vivo drug absorption, Mol. Pharm. 7 (2010) 1431-1440; DOI: 10.1021/mp100109a.

33. E. Scheubel, M. Lindenberg, E. Beyssac and J. M. Cardot, Small volume dissolution testing as a powerful method during pharmaceutical development, Pharmaceutics 2 (2010) 351-363; DOI: 10.3390/pharmaceutics2040351.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2017: 1.071
5-year IMPACT FACTOR: 1.623

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 99 99 42
PDF Downloads 16 16 7